37 articles - From Saturday Feb 12 2022 to Friday Feb 18 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint. Circulating neutrophils from patients with arthritis resemble those from healthy controls, but joint fluid cells exhibit a network of changes, conserved across species, that implicate IFN- |
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes. |
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Although the primary endpoint was not met, anifrolumab IR was associated with numerical improvements over placebo across endpoints, including CRR, in patients with active lupus nephritis. |
Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren's syndrome. The ANA and RF repertoires in patients with SjS display tissue-restricted, antigen-dependent and divergent affinity maturation. Affinity maturation of RF clones deviates further during RF clone derived lymphomagenesis and during regeneration of the autoreactive repertoire after temporary disruption by rituximab. These data give insight into the molecular mechanisms of autoreactive inflammation in SjS, assist MALT lymphoma diagnosis and allow tracking its response to rituximab. |
| Arthritis Care Res (Hoboken) |
Development of a natural language processing system for extracting rheumatoid arthritis outcomes from clinical notes using the national RISE registry. We developed an NLP pipeline to extract RA outcome measures from a national registry of notes from multiple EHR systems and found it to have good internal and external validity. This pipeline can facilitate measurement of clinical and patient reported outcomes for use in research and quality measurement. |
Using patient-reported health data from social media to identify diverse lupus patients and assess their symptom and medication expressions: A feasibility study. Our results indicate that social media surveillance can provide valuable lupus patient perspective data of clinical relevance. The medical community has the opportunity to harness this information to inform the patient-centered care within underrepresented patient groups such as POC. |
| Arthritis Res Ther |
A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis. CCL22, RANTES, CXCL16, CXCL11, and IL-16 were identified as the major chemokines involved in the recruitment of immune cells in the vascular tissue of patients with TAK. Additionally, the persistently high levels of CCL22, CXCL11, and IL-16 observed after treatment indicate their role in vascular chronic inflammation or fibrosis and demonstrate the need for developing more efficacious treatment options. |
CD34+THY1+ synovial fibroblast subset in arthritic joints has high osteoblastic and chondrogenic potentials in vitro. The CD34 + THY1 + SF subset has high osteogenic and chondrogenic potentials. The preferential enhancement of MSC functions in the CD34 + THY1 + subset may provide a new treatment strategy for regenerating damaged bone/cartilage in arthritic joints. |
Chondrocyte-derived exosomes promote cartilage calcification in temporomandibular joint osteoarthritis. Abnormal biomechanical loading leads to enhanced formation of chondrocyte-derived exosomes, in which promoters of calcification increased and inhibitors decreased, resulting in accelerating abnormal cartilage calcification in TMJ OA. The inhibition of degenerative chondrocyte-derived exosomes is expected to be a new way to prevent and treat TMJ OA. |
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. Gut dysbiosis, more frequent in AS patients than controls, is associated with worse axSpA disease activity and physical function, seemingly irrespective of both gut inflammation and treatments. This provides further evidence for an important link between disturbances in gastrointestinal homeostasis and axSpA. |
Increased oxidative stress contributes to impaired peripheral CD56dimCD57+ NK cells from patients with systemic lupus erythematosus. Our study demonstrated a selective loss of mature CD56 dim CD57 + NK cell subset in SLE patients, which may caused by preferential apoptosis of this subset under increased oxidative stress in SLE. The attenuated in vitro cytotoxicity of CD56 dim CD57 + NK cells may contribute to the impaired ability of eliminating pathogenic CD4 + T cells in SLE. |
Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. In patients with early RA achieving clinical remission, patient function (HAQ-DI), and MRI measures of bone damage (erosion) predicted disease flare 6 and 12 months after treatment withdrawal. These variables may help identify patients with early RA in clinical remission as candidates for successful treatment withdrawal. |
Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals. The changes in cryoglobulinemia mortality during the past two decades are mainly related to the aging and dying of the "baby boomer" cohort who had a high HCV prevalence and to the introduction of a DAA in 2014. |
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Twenty-four-week belimumab discontinuation did not appear to increase the risk of flares or rebound in patients with low SLE disease activity; flare rates were low in both groups. Further studies may help to fully determine the effect of belimumab discontinuation. |
Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. Pembrolizumab specifically activated intermediate monocytes and induced the production of several cytokines including TNFa but not IL-6. These findings indicate that flares in patients with pre-existing inflammatory arthritis involve monocyte activation and could be managed with TNFa neutralization. |
| Arthritis Rheumatol |
B cell-specific deletion of Crif1 drives lupus-like autoimmunity by activation of IL-17, IL-6, and pathogenic Tfh cells. These results showed that Crif1 was negatively correlated with disease severity, and overexpression of Crif1 ameliorated disease development. Our findings suggest that Crif1 is essential for preventing lupus development by maintaining B cell self-tolerance. |
Characterization of Blood Mucosal Associated Invariant T (MAIT) cells in Axial Spondyloarthritis and of resident MAITs from control axial enthesis. Both blood MAITs and resident MAITs in axial entheses contribute to IL-17 production and may play important roles in AxSpA pathogenesis. |
Endothelial cell-activating antibodies in COVID-19. These data are the first to suggest that some patients with COVID-19 have potentially diverse antibodies that drive endotheliopathy, adding important context regarding thrombo-inflammatory effects of autoantibodies in severe COVID-19. |
The prominent role of hematopoietic peptidyl arginine deiminase 4 in arthritis: collagen and G-CSF induced arthritis model in C57BL/6 mice. We succeeded in developing an arthritis model suitable for use in C57BL/6 mice that was fully compliant with high animal welfare standards. We observed an over 90% incidence of arthritis in male mice and detectable NET markers. This model, with some futures consistent with human RA, demonstrates that hematopoietic PAD4 is an important contributor to arthritis development and may prove useful in future RA research. |
| Rheumatology (Oxford) |
Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Anti-Ro52 antibodies were highly prevalent in patients with anti-MDA5 and anti-Jo1 antibodies. Within al patients with IIM-ILD, those with anti-Ro52 autoantibodies had a higher frequency of RP-ILD and a poorer prognosis, especially in the anti-MDA5 antibody subgroup. |
Defining Imaging Sub-phenotypes of Psoriatic Arthritis: Integrative Analysis of Imaging Data and Gene Expression in a PsA Patient Cohort. We identified three sub-phenotypes based on the predominant tissue involved in patients with active PsA. Distinct biological pathways may underlie these imaging sub-phenotypes seen in PsA, suggesting their biological and clinical importance. |
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. In the placebo group of the SENSCIS trial, the rate of FVC decline was similar irrespective of the presence of cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough or dyspnoea at baseline, but no statistically significant heterogeneity was observed between the subgroups. |
IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in Systemic Sclerosis epidermis. These results show that IL-25 participates to skin homeostasis and its decreased expression in SSc may contribute to skin fibrosis by favoring ECM deposition over degradation. |
Predictors of rapidly progressive- interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Anti-MDA5-associated RP-ILD is significantly associated with poor survival rates. The "FLAW" model maybe useful to predict the development of RP-ILD. |
Plenty of the editorials are available as full text through the publisher website using the provided link
Letters to the editors and authors’ replies
all remaining publications eg case reports, images of the month, etc…
| Ann Rheum Dis |
| Arthritis Rheumatol |
| Rheumatology (Oxford) |